Assay development
Our biologists adapt and develop industry standard assays needed for screening, hit confirmation and functional characterisation of new molecules.
Screening
We carry out high-throughput screening using proprietary in-house compound libraries. For antibody projects we screen antibodies for binding to the target antigen.
Hit to lead optimisation
Our medicinal chemists develop structure-activity relationships (SAR) to improve potency, solubility and physico-chemical properties of hit series to turn them into drug-like molecules. For antibody projects we generate humanised or fully human antibodies and engineer them to obtain optimal binding affinity, functional efficacy and robust biophysical properties to generate a lead candidate.
Proof of concept
We evaluate our candidate compounds and antibodies in a range of relevant models, including human tissue, to demonstrate disease relevance and target engagement.
Partnering
We develop novel IP and a robust supporting data package suitable for partnering to pharmaceutical or biotechnology companies.
Accessing our expertise
Teams of nearly 80 scientists in our new Centre for Therapeutics.
Discovery offering:
- ADME/DMPK
- Assay development
- Antibody biophysical characterisation
- Antibody engineering
- Antibody humanisation
- High-throughput screening
- Medicinal chemistry
- Pharmacology
- Small molecule libraries
- Structural biology in silicoscreening
Screening against our compound library
120,000+ compounds, including:
- Annotated sets of pharmacologically active compounds
- Approved drugs
- Fragments
- Ion channel focused compounds
- Kinase targeting compounds
- Natural products
- Protein-protein interaction targeting compounds